Mirna Therapeutics Inc., after raising tens of millions of dollars in venture capital and research grants and going public, has reached the end of the road.
The Austin-based biotech company halted drug development last year following deaths of patients in clinical trials— now it is being acquired by a Boston-area suitor in a reverse merger.
Synlogic Inc. of Cambridge, Massachusetts, which focuses on drugs that affect bacteria in the gut, announced Tuesday its merger with Mirna (Nasdaq: MIRN), which will result in the company departing the Texas capital.
